Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
2000 1
2008 3
2009 1
2011 3
2012 3
2013 4
2014 4
2015 7
2016 5
2017 4
2018 8
2019 5
2020 16
2021 9
2022 4
Text availability
Article attribute
Article type
Publication date

Search Results

63 results
Results by year
Filters applied: . Clear all
Page 1
Showing results for ivan visit
Your search for Ivan Višić retrieved no results
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.
Balwani M, Sardh E, Ventura P, Peiró PA, Rees DC, Stölzel U, Bissell DM, Bonkovsky HL, Windyga J, Anderson KE, Parker C, Silver SM, Keel SB, Wang JD, Stein PE, Harper P, Vassiliou D, Wang B, Phillips J, Ivanova A, Langendonk JG, Kauppinen R, Minder E, Horie Y, Penz C, Chen J, Liu S, Ko JJ, Sweetser MT, Garg P, Vaishnaw A, Kim JB, Simon AR, Gouya L; ENVISION Investigators. Balwani M, et al. N Engl J Med. 2020 Jun 11;382(24):2289-2301. doi: 10.1056/NEJMoa1913147. N Engl J Med. 2020. PMID: 32521132 Clinical Trial.
(Composite porphyria attacks resulted in hospitalization, an urgent health care visit, or intravenous administration of hemin at home.) Key secondary end points were levels of ALA and porphobilinogen and the annualized attack rate among patients with acute hepatic porphyri …
(Composite porphyria attacks resulted in hospitalization, an urgent health care visit, or intravenous administration of hemin at home …
Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti-Vascular Endothelial Growth Factor Agents.
Evans RN, Reeves BC, Maguire MG, Martin DF, Muldrew A, Peto T, Rogers C, Chakravarthy U. Evans RN, et al. JAMA Ophthalmol. 2020 Oct 1;138(10):1043-1051. doi: 10.1001/jamaophthalmol.2020.3001. JAMA Ophthalmol. 2020. PMID: 32816002 Free PMC article. Clinical Trial.
DESIGN, SETTING, AND PARTICIPANTS: In this study using data from the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) and the Inhibition of VEGF in Age-Related Choroidal Neovascularization (IVAN) randomized clinical trial, people with previously untr …
DESIGN, SETTING, AND PARTICIPANTS: In this study using data from the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) …
Differences Between Neurosurgical Subspecialties in Telehealth Adoption.
Basil GW, Eichberg DG, Perez-Dickens M, Menendez I, Ivan ME, Urakov T, Komotar RJ, Wang MY, Levi AD. Basil GW, et al. World Neurosurg. 2021 Feb;146:e323-e327. doi: 10.1016/j.wneu.2020.10.080. Epub 2020 Nov 16. World Neurosurg. 2021. PMID: 33212275 Free PMC article.
CONCLUSIONS: There were clear trends with regard to which pathologies and procedures were most amenable to telehealth visits, which suggests a potential roadmap for future clinic planning. ...
CONCLUSIONS: There were clear trends with regard to which pathologies and procedures were most amenable to telehealth visits, which s …
Long-term Visual Outcomes after Release from Protocol in Patients who Participated in the Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN) Trial.
Evans RN, Reeves BC, Phillips D, Muldrew KA, Rogers C, Harding SP, Chakravarthy U; IVAN Study Group. Evans RN, et al. Ophthalmology. 2020 Sep;127(9):1191-1200. doi: 10.1016/j.ophtha.2020.03.020. Epub 2020 Mar 27. Ophthalmology. 2020. PMID: 32359843 Free PMC article. Clinical Trial.
PARTICIPANTS: Patients enrolled in the Inhibition of VEGF in Age-related choroidal Neovascularisation (IVAN) trial; after excluding participants from 2 sites and who died or withdrew during the trial, 537 were included in this follow-up cohort. ...RESULTS: Data were obtain …
PARTICIPANTS: Patients enrolled in the Inhibition of VEGF in Age-related choroidal Neovascularisation (IVAN) trial; after excluding p …
Songwriting and science.
Stewart CN Jr. Stewart CN Jr. Science. 2015 Jul 24;349(6246):446. doi: 10.1126/science.349.6246.446. Science. 2015. PMID: 26206938 No abstract available.
[Professor Ivan Tarchanoff].
Widacki J. Widacki J. Przegl Lek. 2015;72(1):45-8. Przegl Lek. 2015. PMID: 26076579 Polish.
He was more than just a teacher and a friend of Cybulski: after being dismissed from the Academy in St Petersburg , the scientist not only used to visit Krakow but published his scientific works here, built a house in the vicinity of the city, and here he died on 24th Augu …
He was more than just a teacher and a friend of Cybulski: after being dismissed from the Academy in St Petersburg , the scientist not only u …
SARS-CoV-2 Seropositivity and Seroconversion in Patients Undergoing Active Cancer-Directed Therapy.
Sun L, Surya S, Goodman NG, Le AN, Kelly G, Owoyemi O, Desai H, Zheng C, DeLuca S, Good ML, Hussain J, Jeffries SD, Kry YR, Kugler EM, Mansour M, Ndicu J, Osei-Akoto A, Prior T, Pundock SL, Varughese LA, Weaver J, Doucette A, Dudek S, Verma SS, Gouma S, Weirick ME, McAllister CM, Bange E, Gabriel P, Ritchie M, Rader DJ, Vonderheide RH, Schuchter LM, Verma A, Maillard I, Mamtani R, Hensley SE, Gross R, Wileyto EP, Huang AC, Maxwell KN, DeMichele A. Sun L, et al. JCO Oncol Pract. 2021 Dec;17(12):e1879-e1886. doi: 10.1200/OP.21.00113. Epub 2021 Jun 16. JCO Oncol Pract. 2021. PMID: 34133219
RESULTS: Of 124 enrolled patients, only two (1.6%) had detectable SARS-CoV-2 antibodies on initial blood draw, and no initially seronegative patients developed newly detectable antibodies on subsequent blood draw(s), corresponding to a seroconversion rate of 0% (95% CI, 0.0 TO 4. …
RESULTS: Of 124 enrolled patients, only two (1.6%) had detectable SARS-CoV-2 antibodies on initial blood draw, and no initially seronegative …
Neuro-oncology practice guidelines from a high-volume surgeon at the COVID-19 epicenter.
Luther E, Burks J, Eichberg DG, Basil G, Berry K, Lu V, Shah A, Kaur G, Ivan M, Komotar R. Luther E, et al. J Clin Neurosci. 2021 Mar;85:1-5. doi: 10.1016/j.jocn.2020.12.012. Epub 2020 Dec 16. J Clin Neurosci. 2021. PMID: 33581778 Free PMC article.

RESULTS: From 3/23/20-7/20/20, 469 clinic visits and 196 surgeries were identified. After quarantine was lifted, face-to-face visits increased (P < 0.01) yet no change in telehealth visits occurred. Of 327 telehealth visits, only 5.8% converted to i

RESULTS: From 3/23/20-7/20/20, 469 clinic visits and 196 surgeries were identified. After quarantine was lifted, face-to-face visi
Intralesional Macular Atrophy in Anti-Vascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration in the IVAN Trial.
Bailey C, Scott LJ, Rogers CA, Reeves BC, Hamill B, Peto T, Chakravarthy U, Harding SP; writing committee for the IVAN Study Group. Bailey C, et al. Ophthalmology. 2019 Jan;126(1):75-86. doi: 10.1016/j.ophtha.2018.07.013. Epub 2018 Oct 6. Ophthalmology. 2019. PMID: 30301555 Free article. Clinical Trial.
RESULTS: Study eye data were available for 594 of 610 participants; 57 (9.6%) showed intralesional MA at baseline. Incident intralesional MA occurred in 24.4% by the final visit and extralesional MA in only 1.54%. In fellow eyes, an established nAMD lesion was present at b …
RESULTS: Study eye data were available for 594 of 610 participants; 57 (9.6%) showed intralesional MA at baseline. Incident intralesional MA …
63 results